Cerene Cryotherapy Device
Channel Medsystems, Inc. · Decision date Mar 28, 2019
What did the FDA approve?
FDA records P180032 as an original PMA application. The recorded decision is approval, dated Mar 28, 2019.
FDA approval order statement
Approval for the Cerene Cryotherapy Device. This device is indicated for endometrial cryoablation in premenopausal women with heavy menstrual bleeding due to benign causes for whom child bearing is complete.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Obstetrics/Gynecology
- Decision date
- Mar 28, 2019
Regulatory record facts
- Identifier
- P180032
- Regulatory pathway
- Premarket approval application
- Applicant
- Channel Medsystems, Inc.
- Product code
- MNB
- Decision code
- APPR
- Decision date
- Mar 28, 2019
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, thermal ablation, endometrial.
- Applicant
- Channel Medsystems, Inc.
- Product code
- MNB
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P180032 received
Application receipt date recorded by FDA.
P180032 · FDA decision
APPR
P180032/S024 · Related supplement
Cerene Cryotherapy Device
P180032/S025 · Related supplement
Cerene Cryotherapy Device (Model number FGS-7000); Exhaust Collection Bag (Model number FGS-8000); Exhaust Collection Ba
Timeline entries are records held by MedtechLedger for P180032. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180032
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Cerene Cryotherapy DeviceP180032/S024 | Channel Medsystems, Inc. | PMA supplement | Sep 15, 2026 | FDA |
| Channel Medsystems, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Explore the linked device profile
Other records with product code MNB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MINERVA ENDOMETRIAL ABLATION SYSTEMP140013/S019 | Axora Medical, Inc. | PMA supplement | Nov 5, 2026 | FDA |
| Axora Medical, Inc. | PMA approval | Jul 27, 2015 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Channel Medsystems, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5858 Horton St., Suite 200, Emeryville, CA, 94608
Sources and methodology
- Original FDA record: P180032
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


